Ground Hog Day For Merck: FDA Again Cancels Sugammadex Advisory Committee Review
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is conducting additional inspections of the site of a hypersensitivity study the agency requested in 2008; concerns about the study derailed a committee review in 2013.